Looking Back on 2022 and Ahead to 2023
2022 was an amazing year at Torigen filled with continued growth and success. We’ve continued to work on improving the lives of pets, treating thousands of companion animals and giving veterinarians and pet parents alike more options in the fight against cancer.
We had a number of exciting milestones in 2022, but here are a few highlights from the year:
We expanded our histopathology services with Vidium Animal Health.
A definitive cancer diagnosis is necessary for Torigen to create our experimental autologous cancer immunotherapy. The combination of Vidium’s industry leading oncopathologists with Torigen’s expert veterinary oncologists provides veterinarians with a precise diagnosis and an innovative cancer treatment plan. We are excited to see this strategic partnership enhance Torigen’s ability to provide advanced cancer care solutions for companion animals.
We entered into a preferred partnership with VerticalVet.
The Preferred Partnership Agreement with VerticalVet, announced in December, will give Torigen access to their 2,000+ clinic Group Purchasing Organization. This partnership will expand Torigen’s ability to deliver innovative companion animal cancer treatments to a larger patient population, while allowing more clinicians to be part of the veterinary oncology solution and provide more cancer treatment options.
We inked a National Distribution agreement with MWI.
Torigen entered into its first national distribution agreement with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen. The agreement expands access to Torigen’s experimental autologous cancer vaccine for companion animals. MWI, the premier distributor for both private- and corporate-owned veterinary clinics, supports the distribution of tumor collection kits to veterinarians across the country.
Torigen successfully completed a $13 Million Series A round capital raise.
In November, we announced that Torigen closed its $13 million Series A1 round led by Werth Family Investment Associates, LLC and Connecticut Innovations, Inc., bringing the total raised by the company to $18 million. Existing investors Emerald Development Managers, Gaingels, Kema Fund, University of Notre Dame, SoGal Ventures, and UCONN Innovation Fund, LLC participated in the round. New investors in this round also included Ironwood Capital and Advantage Capital. This additional investment will enable Torigen to continue developing a product pipeline and deliver affordable, accessible treatments to pet owners.
We hope to continue this success into 2023 with a few goals in mind….
At Torigen, we aim to harness the power of the immune system to advance veterinary medicine. We are excited to expand our pipeline and by the end of this year, we will have exciting updates to share.
We aim to build a distinguished company focused on our leadership, superior customer service and conscientiousness.
It’s our goal to continue making a difference in the lives of pets with devastating illnesses. We know we are building something special at Torigen and will always appreciate the help and support of our incredible community.
Want to learn more about Torigen? Contact us today.